Evidence map›Paper›PMID 41350890›Full record

ReviewItalian journal of pediatrics2025

Advances in multi-omics and therapeutic studies of Henoch-Schönlein purpura.

Mengyan Xu, Zhuohang Wei, Lu Wang, Wenjuan Liang, Fei Gao, Shenggang Sang, Rongguang Zhang

Abstract readReview
In one paragraph

Review in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengyan XuSchool of Public Health & Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, 571199, China.
Zhuohang WeiSchool of Public Health & Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, 571199, China.
Lu WangSchool of Public Health & Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, 571199, China.
Wenjuan LiangSchool of Public Health & Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, 571199, China.
Fei GaoFirst Affiliated Hospital, Hainan Medical University, Haikou, 570102, China.
Shenggang SangFirst Affiliated Hospital, Hainan Medical University, Haikou, 570102, China. lytssg@126.com.
Rongguang ZhangSchool of Public Health & Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, 571199, China. zrg@zzu.edu.cn.ORCID http://orcid.org/0000-0001-9961-2434

Funding

National Natural Science Foundation of China 82160634
6 · The paper itself

Abstract

Henoch-Schönlein purpura (HSP) is a vasculopathic disease due to lesions in blood vessels, and patients with HSP presenting with renal injury are at risk of further progression to end-stage renal disease, resulting in a severe disease burden, the pathogenesis of which is currently unclear. By integrating multi-omics data, biomarkers and signaling pathways that are specifically expressed in HSP can be screened, thus finding new perspectives for resolving the pathogenesis of HSP. The aim of this review is to explore the developmental pathways of HSP and to reveal key biomarkers and therapeutic targets. Finally, we discuss the therapeutic approaches to HSP, with the hope that these insights will drive the future development of personalized medicine and improve patient prognosis and quality of life.

Indexed as

IgA VasculitisBiomarkersHumansMultiomicsPrecision MedicineProteomicsBiomarkersBiomarkerHenoch-Schönlein purpuraMulti-omicsSignaling pathwayTreatment

Identifiers

PMID41350890
PMCPMC12797630

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.